Henrik Elofsson
Plus aucun poste en cours
Historique de carrière de Henrik Elofsson
Anciens postes connus de Henrik Elofsson
Sociétés | Poste | Début | Fin |
---|---|---|---|
MENDUS AB | Directeur des opérations | 01/07/2013 | - |
Arterion AB
Arterion AB BiotechnologyHealth Technology Arterion AB is a holding company that manufactures biomaterials, including artificial blood vessels, consisting of microbial derived cellulose for revascularization of patients with cardiovascular diseases. It focuses on pure uncoated cellulose grafts as replacement of human vessels, primarily as bypass grafts. Its manufacturing method is based on a novel technology that controls the life conditions of the microbe Gluconacetobacter xylinus. Its use of microbial derived cellulose will allow clinicians to use artificial blood vessels as replacement for vessels with an internal diameter of less than five millimeters. The company was founded on January 4, 2007 and is headquartered in Gothenburg, Sweden. | Directeur/Membre du Conseil | 03/09/2010 | - |
Fondateur | 01/01/2007 | - | |
Corporate Officer/Principal | 03/09/2010 | 11/06/2013 |
Formation de Henrik Elofsson
University of Linköping | Undergraduate Degree |
Chalmers School of Entrepreneurship | Graduate Degree |
Statistiques
Internationale
Suède | 5 |
Opérationnelle
Director/Board Member | 1 |
Founder | 1 |
Corporate Officer/Principal | 1 |
Sectorielle
Health Technology | 3 |
Consumer Services | 3 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Sociétés cotées | 1 |
---|---|
MENDUS AB | Health Technology |
Entreprise privées | 1 |
---|---|
Arterion AB
Arterion AB BiotechnologyHealth Technology Arterion AB is a holding company that manufactures biomaterials, including artificial blood vessels, consisting of microbial derived cellulose for revascularization of patients with cardiovascular diseases. It focuses on pure uncoated cellulose grafts as replacement of human vessels, primarily as bypass grafts. Its manufacturing method is based on a novel technology that controls the life conditions of the microbe Gluconacetobacter xylinus. Its use of microbial derived cellulose will allow clinicians to use artificial blood vessels as replacement for vessels with an internal diameter of less than five millimeters. The company was founded on January 4, 2007 and is headquartered in Gothenburg, Sweden. | Health Technology |
- Bourse
- Insiders
- Henrik Elofsson
- Expérience